Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,030,178
  • Shares Outstanding, K 192,114
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 596 M
  • EBITDA $ 685 M
  • 60-Month Beta 0.26
  • Price/Sales 3.75
  • Price/Cash Flow 19.38
  • Price/Book 2.00

Options Overview Details

View History
  • Implied Volatility 42.55% (-3.16%)
  • Historical Volatility 26.60%
  • IV Percentile 76%
  • IV Rank 54.86%
  • IV High 55.63% on 04/10/25
  • IV Low 26.64% on 03/24/25
  • Expected Move (DTE 23) 4.94 (8.01%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 754
  • Volume Avg (30-Day) 1,334
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 35,643
  • Open Int (30-Day) 31,491
  • Expected Range 56.68 to 66.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.08
  • Number of Estimates 9
  • High Estimate 1.23
  • Low Estimate 0.90
  • Prior Year 0.98
  • Growth Rate Est. (year over year) +10.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.28 +11.94%
on 01/30/26
66.28 -6.63%
on 02/24/26
+5.67 (+10.09%)
since 01/23/26
3-Month
50.90 +21.57%
on 12/15/25
66.28 -6.63%
on 02/24/26
+5.59 (+9.93%)
since 11/25/25
52-Week
50.76 +21.91%
on 11/07/25
73.51 -15.82%
on 03/07/25
-9.29 (-13.05%)
since 02/25/25

Most Recent Stories

More News
BioMarin to Participate in Four Upcoming Investor Conferences in March

SAN RAFAEL, Calif. , Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

BMRN : 61.69 (-1.49%)
BioMarin: Q4 Earnings Snapshot

BioMarin: Q4 Earnings Snapshot

BMRN : 61.69 (-1.49%)
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

BMRN : 61.69 (-1.49%)
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO ®

BMRN : 61.69 (-1.49%)
BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

BMRN : 61.69 (-1.49%)
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

SAN RAFAEL, Calif. , Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

BMRN : 61.69 (-1.49%)
BioMarin Announces Closing of Private Offering of Senior Notes

SAN RAFAEL, Calif. , Feb. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it closed its previously announced offering of $850 million of 5.500%...

BMRN : 61.69 (-1.49%)
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced offering of $850 million of 5.500%...

BMRN : 61.69 (-1.49%)
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

SAN RAFAEL, Calif. , Jan. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850...

BMRN : 61.69 (-1.49%)
BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry

BMRN : 61.69 (-1.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 72.70
2nd Resistance Point 69.49
1st Resistance Point 66.05
Last Price 61.69
1st Support Level 59.41
2nd Support Level 56.20
3rd Support Level 52.76

See More

52-Week High 73.51
Fibonacci 61.8% 64.82
Fibonacci 50% 62.14
Last Price 61.69
Fibonacci 38.2% 59.45
52-Week Low 50.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar